CIK 0001447028 · Non-accelerated filer<br>Smaller reporting company
Arbutus Biopharma Corp
Sign in to watch- Ticker
- ABUS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- EIN
- 980597776
- Phone
- 604-419-3200
- Business address
- 701 VETERANS CIRCLE, WARMINSTER, PA, 18974
- Former names
- TEKMIRA PHARMACEUTICALS CORP, TEKMIRA PHARMACEUTICALS Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-01-20 | Picchio Gaston Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +256,500 | $2.81 | $721K | 256,500 |
| 2022-01-20 | McElhaugh Michael J. Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +325,850 | $2.81 | $916K | 325,850 |
| 2021-12-01 | Sofia Michael J. Chief Scientific Officer | Sale | −200,000 | $5.09 | $1.0M | 1,303,403 |
| 2021-11-09 | Tran Tram Director | Grant or award · Stock Option (Right to Buy) | +44,000 | 44,000 | ||
| 2021-10-18 | Roivant Sciences Ltd. 10% owner | Conversion | +22,833,922 | 38,847,462 | ||
| 2021-10-18 | Roivant Sciences Ltd. 10% owner | Conversion · Series A participating convertible preferred shares | −1,164,000 | 0 | ||
| 2021-06-03 | BURGESS DANIEL D Director | Grant or award · Stock Options | +22,000 | 22,000 | ||
| 2021-06-03 | HENRIQUES RICHARD C JR Director | Grant or award · Stock Options | +22,000 | 22,000 | ||
| 2021-06-03 | Meyers James R Director | Grant or award · Stock Options | +22,000 | 22,000 | ||
| 2021-06-03 | MANCHESTER KEITH S Director | Grant or award · Stock Options | +22,000 | 22,000 | ||
| 2021-06-03 | Cheng Andrew Director | Grant or award · Stock Options | +22,000 | 22,000 | ||
| 2021-06-03 | Torti Frank Director | Grant or award · Stock Options | +22,000 | 22,000 | ||
| 2021-02-13 | Picchio Gaston Chief Development Officer | Grant or award · Stock Options | +250,000 | 250,000 | ||
| 2021-02-13 | HASTINGS DAVID C Chief Financial Officer | Grant or award · Stock Options | +250,000 | 250,000 | ||
| 2021-02-13 | Collier William H. President and CEO | Grant or award · Stock Options | +675,000 | 675,000 | ||
| 2021-02-13 | Howard Elizabeth Chief Compliance Officer | Grant or award · Stock Options | +200,000 | 200,000 | ||
| 2021-02-13 | McElhaugh Michael J. Chief Business Officer | Grant or award · Stock Options | +249,000 | 249,000 | ||
| 2021-02-13 | Sofia Michael J. Chief Scientific Officer | Grant or award · Stock Options | +290,000 | 290,000 | ||
| 2021-02-09 | McElhaugh Michael J. Chief Business Officer | Sale | −20,000 | $5.00 | $100K | 1,307,457 |
| 2020-12-14 | McElhaugh Michael J. Chief Business Officer | Sale | −30,000 | $5.00 | $150K | 1,337,457 |
Page 6 of 8 · 141 trades